We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Senators want probe of biologic companies’ practices

Senate Judiciary Committee Chairman Charles Grassley and Senator Amy Klobuchar have asked the Federal Trade Commission to investigate whether makers of biologic medicines are using practices that hinder or delay biosimilars from entering the market.

According to the Food and Drug Administration, biologic medicines are used to treat chronic illnesses and are complex mixtures that are not easily identified or characterized.

“Biologics play an important role in treating many serious illnesses and are among the fastest growing classes of therapeutic products…Without biosimilar competition, U.S. patients and...

Subscription required to view this article.

This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content

If you do not currently subscribe to FTCWatch please contact us for subscription information:
Email: customerservices@ftcwatch.com
Phone: 202-909-2156

FTCWatch is delivered in the following formats: via email alert and online at mlexwatch.com/ftcwatch